

Request for permission for oral testimony at Idaho
Medicaid's P&T Committee meeting on 04-15-2011

Submission # 3

The following request has been:

☐ Approved

☒ Denied

Gennrich, Jane - Medicaid

From: Eide, Tamara J. - Medicaid
Sent: Friday, March 11, 2011 3:55 PM
To: Gennrich, Jane - Medicaid
Subject: FW: Request for oral testimony for upcoming P&T committee meeting
Attachments: Idaho medicaid P&TJalyn.docx

Tami Eide, Pharm.D., BCPS

Medicaid Pharmacy Program Supervisor/Manager
Idaho Department of Health and Welfare
eidet@dhw.idaho.gov
3232 Elder St.
Boise, ID 83705
208-364-1829
800-327-5541 fax

From: Linda Dawson [<mailto:linda.j.dawson@gsk.com>]
Sent: Friday, March 11, 2011 3:38 PM
To: Eide, Tamara J. - Medicaid
Subject: Request for oral testimony for upcoming P&T committee meeting

Greetings Tami,

Attached is a request for an opportunity to speak on Jalyn at your upcoming P&T Medicaid meeting.

Regards, Linda

Linda J. Dawson, Pharm.D., MPH, CPH
Sr. Medical Information Scientist II
GlaxoSmithKline
Medical Information Department
T (919) 483-4177
Fax (919) 315-3081
email: linda.j.dawson@gsk.com
<http://www.gsk.com>

March 10, 2011

Tami Eide, Pharm.D.
eidet@dhw.idaho.gov

Dear Idaho P&T Committee:

Based on the submission guidelines for the public comment process, I would like to request that I be allowed to present key clinical information at your upcoming April 15th 2011 Idaho Medicaid P&T review meeting for a new drug which received FDA approval in 2010.

- *Jalyn*, a fixed-dose combination of dutasteride and tamsulosin, was approved by the FDA in June 2010. *Jalyn* is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. *Jalyn* is a new product since the last review of the BPH drug class by Idaho State Medicaid.
- Thank you in advance for your consideration of my request.

Sincerely,

Robert R Pearson, Pharm. D.
Senior Regional Medical Scientist
GlaxoSmithKline Research and Development
North American Medical Affairs
(801) 718-3122